{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:53:30Z","timestamp":1761155610622},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T00:00:00Z","timestamp":1336003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"},{"start":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T00:00:00Z","timestamp":1336003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal disorder that presents with hemolytic anemia, marrow failure and thrombophilia. During acute attacks, corticosteroid can alleviate the hemolytic paroxysm, but the prolonged administration induces serious toxicity including immunosuppression. So American thoracic society (ATS) for tuberculosis (TB) recommends prophylactic anti-TB medication in patients with a long-term steroid therapy. However, in the patient who was treated for active TB in the past, there are no guidelines of the test for determining patients who have latent TB infection (LTBI) and no recommendations of TB prophylaxis if there is no evidence of reactivation at present. A 40-year-old male patient presented with fever and aggravated weakness for a week. He was diagnosed with PNH a month ago and took corticosteroid for 3 weeks. In the past, he was diagnosed with pulmonary TB and completely cured after treatment. According to guideline, he was not indicated with TB prophylaxis. However, he caught miliary TB, progressed to acute respiratory distress syndrome. We experience this embarrassing case, and emphasize the need to investigate multicentral TB prevalence and to make the guidelines of anti-TB medication in subgroups of hematologic diseases including PNH.<\/jats:p>","DOI":"10.1186\/1476-0711-11-12","type":"journal-article","created":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T10:16:41Z","timestamp":1336040201000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Miliary tuberculosis occurred after immunosuppressive drug in PNH patient with completely cured tuberculosis; a case report"],"prefix":"10.1186","volume":"11","author":[{"given":"Jihyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soojung","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byounghoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naeyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,3]]},"reference":[{"key":"258_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ejim.2010.04.002","volume":"21","author":"S Rachidi","year":"2010","unstructured":"Rachidi S, Musallam KM, Taher AT: A closer look at paroxysmal nocturnal hemoglobinuria. Eur J Intern Med. 2010, 21: 260-267. 10.1016\/j.ejim.2010.04.002","journal-title":"Eur J Intern Med"},{"key":"258_CR2","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1182\/blood-2009-03-195966","volume":"113","author":"RA Brodsky","year":"2009","unstructured":"Brodsky RA: How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2009, 113: 6522-6527. 10.1182\/blood-2009-03-195966","journal-title":"Blood"},{"key":"258_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.bbmt.2008.11.001","volume":"15","author":"CJ Parker","year":"2009","unstructured":"Parker CJ, Brodsky RA, Levine JE: Treatment versus transplant for challenging hematologic disorders. Biol Blood Marrow Transplant. 2009, 15: 72-78.","journal-title":"Biol Blood Marrow Transplant"},{"key":"258_CR4","first-page":"1","volume":"49","author":"Centers for Disease Control and Prevention (CDC)","year":"2000","unstructured":"Centers for Disease Control and Prevention (CDC): Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR. 2000, 49: 1-51.","journal-title":"MMWR"},{"key":"258_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1473-3099(05)70163-8","volume":"5","author":"SK Sharma","year":"2005","unstructured":"Sharma SK, Mohan A, Sharma A, Mitra DK: Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis. 2005, 5: 415-430. 10.1016\/S1473-3099(05)70163-8","journal-title":"Lancet Infect Dis"},{"key":"258_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1378\/chest.73.1.44","volume":"73","author":"A Falk","year":"1978","unstructured":"Falk A, Fuchs GF: Prophylaxis with isoniazid in inactive tuberculosis. A Veterans Administration Cooperative Study XII. Chest. 1978, 73: 44-48. 10.1378\/chest.73.1.44","journal-title":"Chest"},{"key":"258_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5045\/kjh.2010.45.4.269","volume":"45","author":"JS Kim","year":"2010","unstructured":"Kim JS, Lee JW, Kim BK, Lee JH, Chung J: The use of the complement inhibitor eculizumab (Soliris(R)) for treating Korean patients with paroxysmal nocturnal hemoglobinuria. Korean J Hematol. 2010, 45: 269-274. 10.5045\/kjh.2010.45.4.269","journal-title":"Korean J Hematol"},{"key":"258_CR8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006, 355: 1233-1243. 10.1056\/NEJMoa061648","journal-title":"N Engl J Med"},{"key":"258_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4046\/trd.2008.65.2.79","volume":"65","author":"TS Shim","year":"2008","unstructured":"Shim TS, Koh WJ, Yim JJ, Lew WJ: Treatment of Latent Tuberculosis Infection in Korea. Tubercul Respir Dis. 2008, 65: 79-90. 10.4046\/trd.2008.65.2.79.","journal-title":"Tubercul Respir Dis"},{"key":"258_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","volume":"15","author":"P Lobue","year":"2010","unstructured":"Lobue P, Menzies D: Treatment of latent tuberculosis infection: an update. Respirology. 2010, 15: 603-622. 10.1111\/j.1440-1843.2010.01751.x","journal-title":"Respirology"},{"key":"258_CR11","volume-title":"Global Tuberculosis Control: A Short Update to the 2009 Report","author":"World Health Organization","year":"2009","unstructured":"World Health Organization: Global Tuberculosis Control: A Short Update to the 2009 Report. 2009,"},{"key":"258_CR12","first-page":"781","volume":"49","author":"TS Shim","year":"2006","unstructured":"Shim TS: Comparison of guidelines for the management of tuberculosis: Korea, United States, and World Health Organization. J Korean Med Sci. 2006, 49: 781-789.","journal-title":"J Korean Med Sci"},{"key":"258_CR13","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMcp021045","volume":"347","author":"RM Jasmer","year":"2002","unstructured":"Jasmer RM, Nahid P, Hopewell PC: Clinical practice. Latent tuberculosis infection. N Engl J Med. 2002, 347: 1860-1866. 10.1056\/NEJMcp021045","journal-title":"N Engl J Med"},{"key":"258_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10875-007-9084-0","volume":"27","author":"K Bhatt","year":"2007","unstructured":"Bhatt K, Salgame P: Host innate immune response to Mycobacterium tuberculosis. J Clin Immunol. 2007, 27: 347-362. 10.1007\/s10875-007-9084-0","journal-title":"J Clin Immunol"},{"key":"258_CR15","first-page":"1110","volume":"90","author":"FA Silva","year":"2005","unstructured":"Silva FA, Matos JO, de QMFC, Nucci M: Risk factors for and attributable mortality from tuberculosis in patients with hematologic malignances. Haematologica. 2005, 90: 1110-1115.","journal-title":"Haematologica"},{"key":"258_CR16","first-page":"161","volume":"25","author":"JS Hahn","year":"1990","unstructured":"Hahn JS, Lee YC, Kim YK, Lee SJ, Ko YW, Chang J, Lee WY: Clinical study on tuberculosis in patients with hematologic disease. Korean J Hematol. 1990, 25: 161-169.","journal-title":"Korean J Hematol"},{"key":"258_CR17","first-page":"1","volume-title":"WHO report 2012","author":"World Health Organization (WHO)","year":"2010","unstructured":"World Health Organization (WHO): WHO report 2010 Global tuberculosis control. WHO report 2012. 2010, 1-218."},{"key":"258_CR18","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2169\/internalmedicine.48.2080","volume":"48","author":"K Sugino","year":"2009","unstructured":"Sugino K, Gocho K, Ota H, Kobayashi M, Sano G, Isobe K, Takai Y, Izumi H, Kuraishi Y, Shibuya K, Homma S: Miliary tuberculosis associated with chronic neutrophilic leukemia. Intern Med. 2009, 48: 1283-1287. 10.2169\/internalmedicine.48.2080","journal-title":"Intern Med"},{"key":"258_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1476-0711-7-8","volume":"7","author":"IK Neonakis","year":"2008","unstructured":"Neonakis IK, Alexandrakis MG, Gitti Z, Tsirakis G, Krambovitis E, Spandidos DA: Miliary tuberculosis with no pulmonary involvement in myelodysplastic syndromes: a curable, yet rarely diagnosed, disease: case report and review of the literature. Ann Clin Microbiol Antimicrob. 2008, 7: 8- 10.1186\/1476-0711-7-8","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-0711-11-12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/1476-0711-11-12\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-0711-11-12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:40:09Z","timestamp":1630525209000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/1476-0711-11-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,3]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["258"],"URL":"https:\/\/doi.org\/10.1186\/1476-0711-11-12","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,3]]},"assertion":[{"value":"5 January 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"12"}}